References

Agnew JE, Pavia D, Clarke SW (1985) Factors affecting the 'alveolar deposition' of 5 microns inhaled particles in healthy subjects. Clin Phys Physiol Meas 6: 27-36.

Bennett WD (1991) Aerosolized drug delivery: fractional deposition ofinhaled particles. J Aerosol Med 4: 223-7.

Bennett WD, Messina MS, Smaldone GC (1985) Effect of exercise on deposition and subsequent retention of inhaled particles. J Appl Physiol 59: 1046-54.

Camner P, Mossberg B, Philipson K, Strandberg K (1979) Elimination of test particles from the human tracheobron-chial tract by voluntary coughing. Scand JResp Dis 60: 56-62.

Cherrie JW, Aitken RJ (1999) Measurement of human exposure to biologically relevant fractions of inhaled aerosols. Occup Environ Med 56: 747-52.

DeMuro RL, Nafziger AN, Blask DE et al (2000) The absolute bioavailability of oral melatonin. J Clin Pharmacol 40: 781-4.

Harrison LI (2000) Commentary on the FDA draft guidance for bioequivalence studies for nasal aerosols and nasal sprays for local action: an industry view. J Clin Pharmacol 40: 701-7.

Hoffmann W (1996) Modeling techniques for inhaled particle deposition: the state of the art. J Aerosol Med 9: 369-88.

Legath L, Naus A, Halik J (1988) Determining the basic characteristics of aerosols suitable for studies of deposition in the respiratory tract. J Hyg Epidemiol Microbiol Immunol 32: 287-97.

Lippmann M, Yeates DB, Albert RE (1980) Deposition, retention, and clearance of inhaled particles. Br J Indust Med 37: 337-62.

Padfield JM (1985) Making drugs into medicines. In Burley DM, Binns TB (eds), Pharmaceutical Medicine. Arnold: London and New York; 51.

Patel P, Mukai D, Wilson AF (1990) Dose-response effects of two sizes of monodispersed isoproterenol in mild asthma. Am Rev Resp Dis 141: 357-60.

Snell NJ, Ganderton D (1999) Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, UK, April 17 1998. Resp Med 93: 123-33.

Strazis KP, Fox AW (1993) Malignant hyperthermia: A review of published cases. Anesth Analg 77: 297-304.

Zanen P, Go LT, Lammers JW (1996) Optimal particle size for -2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 51: 977-80.

Dealing With Asthma Naturally

Dealing With Asthma Naturally

Do You Suffer From ASTHMA Chronic asthma is a paralyzing, suffocating and socially isolating condition that can cause anxiety that can trigger even more attacks. Before you know it you are caught in a vicious cycle Put an end to the dependence on inhalers, buying expensive prescription drugs and avoidance of allergenic situations and animals. Get control of your life again and Deal With Asthma Naturally

Get My Free Ebook


Post a comment